These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Immunotherapy in gynecological cancers: where are we? Polastro L; Closset C; Kerger J Curr Opin Oncol; 2020 Sep; 32(5):459-470. PubMed ID: 32675594 [TBL] [Abstract][Full Text] [Related]
5. Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors. Grywalska E; Sobstyl M; Putowski L; Roliński J Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547532 [TBL] [Abstract][Full Text] [Related]
6. Update on immune checkpoint inhibitors in gynecological cancers. Heong V; Ngoi N; Tan DS J Gynecol Oncol; 2017 Mar; 28(2):e20. PubMed ID: 28028993 [TBL] [Abstract][Full Text] [Related]
7. New insight in endocrine-related adverse events associated to immune checkpoint blockade. Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543 [TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint blockades in gynecological cancers: A review of clinical trials. Peng H; He X; Wang Q Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489 [TBL] [Abstract][Full Text] [Related]
11. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches. Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277 [TBL] [Abstract][Full Text] [Related]
12. The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers. Kooshkaki O; Derakhshani A; Safarpour H; Najafi S; Vahedi P; Brunetti O; Torabi M; Lotfinejad P; Paradiso AV; Racanelli V; Silvestris N; Baradaran B Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708748 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in Gynecologic Cancers: Are We There Yet? Pakish JB; Jazaeri AA Curr Treat Options Oncol; 2017 Aug; 18(10):59. PubMed ID: 28840453 [TBL] [Abstract][Full Text] [Related]
14. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Hargadon KM; Johnson CE; Williams CJ Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy. McArthur HL; Page DB Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644 [TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint therapy in liver cancer. Xu F; Jin T; Zhu Y; Dai C J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754 [TBL] [Abstract][Full Text] [Related]
18. Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy. Makuku R; Khalili N; Razi S; Keshavarz-Fathi M; Rezaei N J Immunol Res; 2021; 2021():6661406. PubMed ID: 33681388 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of gynecological cancers. Matanes E; Gotlieb WH Best Pract Res Clin Obstet Gynaecol; 2019 Oct; 60():97-110. PubMed ID: 31003902 [TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for cancer treatment. Donátová K; Nováková E; Šupolíková M Klin Onkol; 2022; 35(4):284-289. PubMed ID: 35989085 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]